Figure 1From: A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation Known groups validity: Comparison of scale scores by known groups. *Statistically significant differences between subjects who were currently on treatment and subjects who were not on treatment (p < 0.01). †Statistically significant differences between subjects who indicated that their treatment was extremely to moderately effective and subjects who indicated that their treatment was not effective at all (p < 0.05).Back to article page